First Head-to-Head bDMARD study in axSpA to assess radiographic progression - secukinumab vs. adalimumab biosimilar - 66% of either arm prevented radiographic progression - no difference between two arms but good news is radiographic progression is low! @RheumNow #RNL2023 https://t.co/xq8GhN7kzr